Description of the Efficacy and Safety of Three New Biologics in the Treatment of Rheumatoid Arthritis
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
English articles on abatacept, golimumab, and tocilizumab in rheumatoid arthritis published between 2002 and 2009 were reviewed systematically. All randomized clinical trials, open-label extensions, meta-analyses, and reviews were examined. There were thirteen articles on abatacept, four on golimumab, and seven on tocilizumab. All three drugs were effective in methotrexate-naïve, methotrexate-incomplete responders, and tumor-necrosis-factor-failure rheumatoid arthritis patients. Of the three, only abatacept has been tested in a head-to-head trial with infliximab, in which it was found to be equivalent to infliximab. Golimumab resulted in a more modest improvement than the others in methotrexate-naïve patients, although no direct comparisons among the three drugs were possible or appropriate. Descriptive analysis of adverse events showed that patients receiving abatacept, golimumab, and tocilizumab were subject to more adverse events than controls overall, as expected. In the abatacept studies, a few cases of tuberculosis, more cardiovascular events and gastrointestinal bleedings and more basal cell carcinoma were seen. Golimumab was associated with more skin rashes and pneumonia, while tocilizumab was associated with increased lipids, more liver-function abnormalities, and neutropenia. These new medications are useful additions to the rheumatologic armamentarium and represent greater convenience (golimumab) or different mechanisms of action (abatacept and tocilizumab) than tumornecrosis-factor inhibitors for treating rheumatoid arthritis. As expected, some adverse events occur when using these drugs and patients need to be watched carefully. (Korean J Intern Med 2010;25:1-17)
Abstract
English articles on abatacept, golimumab, and tocilizumab in rheumatoid arthritis published between 2002 and 2009 were reviewed systematically. All randomized clinical trials, open-label extensions, meta-analyses, and reviews were examined. There were thirteen articles on abatacept, four on golimumab, and seven on tocilizumab. All three drugs were effective in methotrexate-naïve, methotrexate-incomplete responders, and tumor-necrosis-factor-failure rheumatoid arthritis patients. Of the three, only abatacept has been tested in a head-to-head trial with infliximab, in which it was found to be equivalent to infliximab. Golimumab resulted in a more modest improvement than the others in methotrexate-naïve patients, although no direct comparisons among the three drugs were possible or appropriate. Descriptive analysis of adverse events showed that patients receiving abatacept, golimumab, and tocilizumab were subject to more adverse events than controls overall, as expected. In the abatacept studies, a few cases of tuberculosis, more cardiovascular events and gastrointestinal bleedings and more basal cell carcinoma were seen. Golimumab was associated with more skin rashes and pneumonia, while tocilizumab was associated with increased lipids, more liver-function abnormalities, and neutropenia. These new medications are useful additions to the rheumatologic armamentarium and represent greater convenience (golimumab) or different mechanisms of action (abatacept and tocilizumab) than tumornecrosis-factor inhibitors for treating rheumatoid arthritis. As expected, some adverse events occur when using these drugs and patients need to be watched carefully. (Korean J Intern Med 2010;25:1-17)
참고문헌 (31)
- Segal B, "Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis", Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 106, pp.778~787 (2008)
- Toussirot E, "The use of TNF-alpha blocking agents in rheumatoid arthritis: an update", Expert Opin Pharmacother, 8, pp.2089~2107 (2007)
- Mertens M, "Anakinra for rheumatoid arthritis: a systematic review", J Rheumatol, 36, pp.1118~1125 (2009)
- Dass S, "Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis", Expert Opin Pharmacother, 7, pp.2559~2570 (2006)
- Kremer JM, "Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis", J Clin Rheumatol, 11(3), pp.S55~S62 (2005)
- Tracey D, "Tumor necrosis factor antagonist mechanisms of action: a comprehensive review", Pharmacol Ther, 117, pp.244~279 (2008)
- Mima T, "Clinical value of blocking IL-6 receptor", Curr Opin Rheumatol, 21, pp.224~230 (2009)
- Westhovens R, "Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors", Ann Rheum Dis, 68, pp.1870~1877 (2009)
- Kremer JM, "Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig", N Engl J Med, 349, pp.1907~1915 (2003)
- Kremer JM, "Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial", Arthritis Rheum, 52, pp.2263~2271 (2005)
- Kremer JM, "Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial", Ann Intern Med, 144, pp.865~876 (2006)
- Genant HK, "Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial", Ann Rheum Dis, 67, pp.1084~1089 (2008)
- Kremer JM, "Results of a twoyear followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate", Arthritis Rheum, 58, pp.953~963 (2008)
- Schiff M, "Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multicentre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate", Ann Rheum Dis, 67, pp.1096~1103 (2008)
- Westhovens R, "Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study", J Rheumatol, 36, pp.736~742 (2009)
- Emery P, "The impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept", Ann Rheum Dis (2009)
- Moreland LW, "Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dosefinding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion", Arthritis Rheum, 46, pp.1470~1479 (2002)
- Genovese MC, "Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition", N Engl J Med, 353, pp.1114~1123 (2005)
- Schiff M, "The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial", Ann Rheum Dis, 68, pp.1708~1714 (2009)
- Westhovens R, "Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial", Rheumatology (Oxford), 45, pp.1238~1246 (2006)
- Emery P, "Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis", Arthritis Rheum, 60, pp.2272~2283 (2009)
- Kay J, "Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study", Arthritis Rheum, 58, pp.964~975 (2008)
- Keystone EC, "Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study", Ann Rheum Dis, 68, pp.789~796 (2009)
- Smolen JS, "Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial", Lancet, 374, pp.210~221 (2009)
- Jones G, "Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study", Ann Rheum Dis, 69, pp.88~96 (2010)
- Maini RN, "Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate", Arthritis Rheum, 54, pp.2817~2829 (2006)
- Nishimoto N, "Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy", Mod Rheumatol, 19, pp.12~19 (2009)
- Smolen JS, "Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebocontrolled, randomised trial", Lancet, 371, pp.987~997 (2008)
- Nishimoto N, "Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab", Ann Rheum Dis, 66, pp.1162~1167 (2007)
- Genovese MC, "Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to diseasemodifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study", Arthritis Rheum, 58, pp.2968~2980 (2008)
- Emery P, "IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial", Ann Rheum Dis, 67, pp.1516~1523 (2008)